Complement-related Innovations: From the immunology laboratories to biotechnology companies
-
1
Unite of Immunology, Military University Hospital of Oran,Algeria, Algeria
-
2
Laboratory of Applied Molecular Biology and Immunology. University of Tlemcen, Algeria
-
3
Department of Biotechnology of Oran, Algeria, Algeria
Increased knowledge about the involvement of complement network in physiology, pathology and homeostasis,the development of high qualified research teams in structural and analytical techniques, and the promising experiences of Eculizumab and Mirococept in human medicine have resulted in thousands of creative approaches on Complement-related Innovations (CRI) in various immunological applications. This paperexposes the biotechnological attractiveness of the over fifty complement proteins in the development of potentially life-saving diagnostic and therapeutic tools that has lead to more than 1,000 patents related to the complement system. We alsohighlight questions about the safety and potential risks of therapeutic complement inhibition. Among the CRI, the development of protein-protein interaction inhibitors has been gaining traction, and monoclonal antibodies or antibody fragments are the most growing class in this field. In fact, many starts up have developed Minibodies (Adienne Laboratory), Aptamers (Ophthotech Laboratory) and Speigelmers (Noxxon laboratory) as alternative macromolecular blocking entities. On the other hand, we discuss the natural concepts-based CRI where biotechnological companies exploit the powerful evasion strategies of microorganisms and parasites to develop more promising drug candidates. Finally, selected examples of complement therapeutics on the market, on clinical trials and in pre-clinical development are highlighted to illustrate the creativity in field.
Keywords:
complement-related innovations,
biotechnologicalmacromolecular blockers,
risks of therapeutic complement inhibition,
creative approaches on Complement-related Innovations (CRI),
complement system
Conference:
The First International Congress of Immunology and Molecular Immunopathology (CIMIP2014), Tlemcen, Algeria, 17 Oct - 20 Oct, 2014.
Presentation Type:
Poster Presentation
Topic:
Immunodeficiencies
Citation:
Kerboua
K,
Meziane
W,
Baba-Hamed
B,
Boumediene
A and
Aribi
M
(2014). Complement-related Innovations: From the immunology laboratories to biotechnology companies.
Front. Immunol.
Conference Abstract:
The First International Congress of Immunology and Molecular Immunopathology (CIMIP2014).
doi: 10.3389/conf.fimmu.2014.04.00026
Copyright:
The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers.
They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.
The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.
Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.
For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.
Received:
03 Oct 2014;
Published Online:
01 Dec 2014.
*
Correspondence:
Dr. Kheir Eddine Kerboua, Unite of Immunology, Military University Hospital of Oran,Algeria, Oran, Algeria, K.K.Eddine@gmail.com